Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes
A secondary (but not primary) dose of the oncolytic virus, VSV, is captured by monocytes and promotes CD8 + T cell recruitment, thereby revealing a mechanism underlying the clinical benefit of repeat dosing in oncolytic virus therapy.
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-12-01
|
| Series: | Communications Biology |
| Online Access: | https://doi.org/10.1038/s42003-022-04254-3 |